Direct comparison of [18F]MH.MZ and [18F]altanserin for 5‐HT2A receptor imaging with PET

Imaging the cerebral serotonin 2A (5‐HT2A) receptors with positron emission tomography (PET) has been carried out in humans with [11C]MDL 100907 and [18F]altanserin. Recently, the MDL 100907 analogue [18F]MH.MZ was developed combining the selectivity profile of MDL 100907 and the favourable radiophysical properties of fluorine‐18. Here, we present a direct comparison of [18F]altanserin and [18F]MH.MZ. 5‐HT2A receptor binding in pig cortex and cerebellum was investigated by autoradiography with [3H]MDL 100907, [18F]MH.MZ, and [18F]altanserin. [18F]MH.MZ and [18F]altanserin were investigated in Danish Landrace pigs by brain PET scanning at baseline and after i.v. administration of blocking doses of ketanserin. Full arterial input function and high performance liquid chromatography (HPLC) analysis allowed for tissue‐compartment kinetic modeling of PET data. In vitro autoradiography showed high binding in cortical regions with both [18F]MH.MZ and [18F]altanserin. Significant 5‐HT2A receptor binding was also found in the pig cerebellum, thus making this region unsuitable as a reference region for in vivo data analysis in this species. The cortical binding of [18F]MH.MZ and [18F]altanserin was blocked by ketanserin supporting that both radioligands bind to 5‐HT2A receptors in the pig brain. In the HPLC analysis of pig plasma, [18F]MH.MZ displayed a fast and reproducible metabolism resulting in hydrophilic radiometabolites only whereas the metabolic profile of [18F]altanserin as expected showed lipophilic radiometabolites. Due to the slow kinetics of [18F]MH.MZ in high‐binding regions in vivo, we suggest that [18F]MH.MZ will be an appropriate tracer for low binding regions where kinetics will be faster, whereas [18F]altanserin is a suitable tracer for high‐binding regions. Synapse, 2013. © 2013 Wiley Periodicals, Inc.

[1]  G. Sedvall,et al.  Autoradiographic localization of 5‐HT2A receptors in the human brain using [3H]M100907 and [11C]M100907 , 2000, Synapse.

[2]  D. Scott,et al.  Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat. , 1998, Journal of pharmaceutical and biomedical analysis.

[3]  Markus Piel,et al.  Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. , 2009, Bioorganic & medicinal chemistry.

[4]  Victor W Pike,et al.  5‐HT radioligands for human brain imaging with PET and SPECT , 2013, Medicinal research reviews.

[5]  G. Knudsen,et al.  An approach for serotonin depletion in pigs: Effects on serotonin receptor binding , 2011, Synapse.

[6]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Olaf B. Paulson,et al.  A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables , 2004, NeuroImage.

[8]  Anders Ettrup,et al.  Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  G. Knudsen,et al.  Direct radiofluorination of [18F]MH.MZ for 5-HT2A receptor molecular imaging with PET , 2012 .

[10]  W C Eckelman,et al.  Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  B. Leonard,et al.  A review of the role of serotonin receptors in psychiatric disorders , 2000, Human psychopharmacology.

[12]  Claus Svarer,et al.  Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  N. Gillings.  A restricted access material for rapid analysis of [(11)C]-labeled radiopharmaceuticals and their metabolites in plasma. , 2009, Nuclear medicine and biology.

[14]  G. Knudsen,et al.  Total synthesis and evaluation of [18F]MHMZ. , 2008, Bioorganic & medicinal chemistry letters.

[15]  D. Holt,et al.  Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons , 2001, Synapse.

[16]  C. Svarer,et al.  Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. , 2010, Archives of general psychiatry.

[17]  A. Luxen,et al.  In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: a film and electronic autoradiographic study. , 1997, Nuclear medicine and biology.

[18]  C. Svarer,et al.  Reduced 5-HT2A receptor binding in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[19]  Mark Slifstein,et al.  Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. Palacios,et al.  Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907 , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  M. Piel,et al.  Preliminary in vivo and ex vivo evaluation of the 5-HT2A imaging probe [(18)F]MH.MZ. , 2009, Nuclear medicine and biology.

[22]  Flemming Andersen,et al.  MR-Based Statistical Atlas of the Göttingen Minipig Brain , 2001, NeuroImage.

[23]  J. Leysen,et al.  Use of 5-HT Receptor Agonists and Antagonists for the Characterization of Their Respective Receptor Sites , 1989 .

[24]  Anders Ettrup,et al.  Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET , 2010, The Journal of Nuclear Medicine.

[25]  Flemming Andersen,et al.  Evaluation of the Novel 5-HT4 Receptor PET Ligand [11C]SB207145 in the Göttingen Minipig , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Gwenn S. Smith,et al.  Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans , 2001, Synapse.

[27]  D. Charney,et al.  Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2a receptors , 1999 .

[28]  Markus Piel,et al.  18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. , 2010, Nuclear medicine and biology.

[29]  J. Kehne,et al.  Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. , 1996, The Journal of pharmacology and experimental therapeutics.

[30]  E. Perry,et al.  5-HT receptor binding in post-mortem brain from patients with affective disorder. , 1987, Journal of affective disorders.

[31]  Robert C. Wolpert,et al.  A Review of the , 1985 .